Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030567 (
Parkinson's disease
)
63,064
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Erectile dysfunction is common among individuals with
Parkinson's disease
, but it is unknown whether it precedes the onset of the classic features of
Parkinson's disease
. To address this question, the authors examined whether erectile dysfunction was associated with
Parkinson's disease
risk in the Health Professionals Follow-up Study. Analyses included 32,616 men free of
Parkinson's disease
at baseline in 1986 who in 2000 completed a retrospective questionnaire with questions on erectile dysfunction in different time periods. Relative risks were computed using Cox proportional hazards models adjusting for age, smoking,
caffeine
intake, history of diabetes, and other covariates. Among men who reported their erectile function before 1986, 200 were diagnosed with
Parkinson's disease
during 1986-2002. Men with erectile dysfunction before 1986 were 3.8 times more likely to develop
Parkinson's disease
during the follow-up than were those with very good erectile function (relative risk = 3.8, 95% confidence interval: 2.4, 6.0; p < 0.0001). Multivariate-adjusted relative risks of
Parkinson's disease
were 2.7, 3.7, and 4.0 (95% confidence interval: 1.4, 11.1; p = 0.008) for participants with first onset of erectile dysfunction (before 1986) at 60 or more, 50-59, and less than 50 years of age, respectively, relative to those without erectile dysfunction. In conclusion, in this retrospective analysis in a large cohort of men, the authors observed that erectile dysfunction was associated with a higher risk of developing
Parkinson's disease
.
...
PMID:Erectile function and risk of Parkinson's disease. 1787 83
Our objective was to assess the association between risk factors for
Parkinson's disease
(PD) and abnormal olfaction in first-degree relatives of patients with PD. Factors including lower cigarette smoking and lower
caffeine
consumption have been associated with increased risk of PD. Idiopathic hyposmia has also been associated with an increased risk of PD. The relationship between risk factors for PD and impaired olfactory function has not been evaluated in relatives of PD patients. We conducted a mail survey of odor identification ability in 173 first-degree relatives of PD patients using the 40-item University of Pennsylvania Smell Identification Test (UPSIT). Respondents also completed a questionnaire inquiring about risk factors for PD including
caffeine
consumption, tobacco use, exercise, and exposures to heavy metals, well-water, and pesticides. There was a direct relationship between olfactory performance and lifetime
caffeine
intake. After adjustment for age, gender, and smoking status, subjects who reported drinking 2 to 3 cups of caffeinated beverages per day (2.6 points higher 95% CI: 0.5, 4.5) and 4 or more cups per day (3.7 points higher, 95% CI: 0.6, 6.7) had significantly better UPSIT scores than those who consumed less than 1 cup per day. There was no significant relationship between olfactory performance and other risk factors. In conclusion, abnormal olfaction is associated with significantly lower lifetime
caffeine
consumption in first-degree relatives of PD patients. Further research is warranted to determine whether a history of lower
caffeine
consumption confers additional risk for the development of PD in hyposmic relatives of PD patients.
...
PMID:Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease. 1787 51
Besides dopaminergic deficiency, other neurotransmitter systems such as noradrenergic nuclei are affected in
Parkinson's disease
. Locus coeruleus degeneration might influence the response to dopamine replacement and the presence of long-term complications such as dyskinesias. In this scenario of noradrenergic and dopaminergic neurodegeneration, behavioural effects induced by dopaminergic-interacting drugs are incompletely known. We investigated whether noradrenergic lesion modulates the levodopa (l-DOPA) response and modifies the response to adenosine antagonists and its interaction with l-DOPA. We examined the motor behaviour induced by: 1) subthreshold doses of l-DOPA (2mg/kg, i.p.), 2) the adenosine-receptor antagonist
caffeine
(10mg/kg), and 3) the combination of l-DOPA (2mg/kg) and
caffeine
(10mg/kg). Each study was done in two experimental conditions: a) rats with unilateral 6-OHDA lesion and b) rats with a lesion of the nigrostriatal pathway (6-OHDA) combined with selective denervation of locus coeruleus-noradrenergic terminal fields by N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4). While only 28% of the 6-OHDA-lesioned animals presented circling behaviour after l-DOPA challenge, all (100%) double-denervated animals rotated after the same l-DOPA dose (p<0.05). No statistical differences in the percentage of rotating animals were observed between single- and double-denervated rats after
caffeine
challenge. Combined l-DOPA-
caffeine
challenge produced rotational behaviour in all (100%) single- and double-denervated rats. No differences in total turns were observed between single- and double-denervated animals in each treatment condition. These findings suggest that additional noradrenergic denervation selectively decreases the motor threshold to l-DOPA treatment without modifying the magnitude or the pattern of the motor response to adenosinergic antagonism.
...
PMID:Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration. 1788 1
Adenosine and its receptors are, as part of the brain stress response, potential targets for neuroprotective drugs. We have investigated if the adenosine receptor system affects the developmental neurotoxicity caused by the fish pollutant methylmercury (MeHg). Behavioral outcomes of low dose perinatal MeHg exposure were studied in mice where the A(1) and A(2A) adenosine receptors were either partially blocked by
caffeine
treatment or eliminated by genetic modification (A(1)R and A(2A)R knock-out mice). From gestational day 7 to day 7 of lactation dams were administered doses that mimic human intake via normal diet, i.e. 1microM MeHg and/or 0.3g/l
caffeine
in the drinking water. This exposure to MeHg resulted in a doubling of brain Hg levels in wild type females and males at postnatal day 21 (PND21). Open field analysis was performed at PND21 and 2 months of age. MeHg caused time-dependent behavioral alterations preferentially in male mice. A decreased response to amphetamine in 2-month-old males pointed to disturbances in dopaminergic functions. Maternal
caffeine
intake induced long-lasting changes in the offspring evidenced by an increased motor activity and a modified response to psychostimulants in adult age, irrespectively of sex. Similar alterations were observed in A(1)R knock-out mice, suggesting that adenosine A(1) receptors are involved in the alterations triggered by
caffeine
exposure during development. Perinatal
caffeine
treatment and, to some extent, genetic elimination of adenosine A(1) receptors, attenuated the behavioral consequences of MeHg in males. Importantly, also deletion of the A(2A) adenosine receptor reduced the vulnerability to MeHg, consistent with the neuroprotective effects of adenosine A(2A) receptor inactivation observed in hypoxia and
Parkinson's disease
. Thus, the consequences of MeHg toxicity during gestation and lactation can be reduced by adenosine A(1) and A(2A) receptor inactivation, either via their genetic deletion or by treatment with their antagonist
caffeine
.
...
PMID:The effects of methylmercury on motor activity are sex- and age-dependent, and modulated by genetic deletion of adenosine receptors and caffeine administration. 1792 Jan 82
Over the last decade, adenosine receptors in the central nervous system have been implicated in the modulation of cognitive functions. Despite the general view that endogenous adenosine modulates cognition through the activation of adenosine A1 receptors, evidence is now emerging on a possible role of A2A receptors in learning and memory. The present review attempts to examine results reported in different studies using diverse animal models, to provide a comprehensive picture of the recent evidence of a relationship between adenosinergic function and memory deficits. The present data suggest that
caffeine
(a nonselective adenosine receptor antagonist) and selective adenosine A2A receptor antagonists can improve memory performance in rodents evaluated through different tasks. They might also afford protection against memory dysfunction elicited in experimental models of aging, Alzheimer's disease,
Parkinson's disease
and, in spontaneously hypertensive rats (SHR), a putative genetic model of attention deficit hyperactivity disorder (ADHD).
...
PMID:Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. 1798 38
Data from Asian populations on dietary and lifestyle factors associated with
Parkinson's disease
are sparse. In 1993-2005, the authors examined these factors in relation to
Parkinson's disease
in the Singapore Chinese Health Study, a prospective cohort of 63,257 Chinese men and women. Baseline data were collected through in-person interviews using structured questionnaires. All 157 incident
Parkinson's disease
cases were identified either through follow-up interviews or via linkage with hospital discharge databases and
Parkinson's disease
outpatient registries and were confirmed by review of medical records. Current versus never smokers exhibited a reduced risk of
Parkinson's disease
(relative risk = 0.29, 95% confidence interval: 0.16, 0.52). Total
caffeine
intake was inversely related to
Parkinson's disease
risk (p for trend = 0.002); the relative risk for the highest versus lowest quartile was 0.55 (95% confidence interval: 0.35, 0.88). Black tea, a
caffeine
-containing beverage, showed an inverse association with
Parkinson's disease
risk that was not confounded by total
caffeine
intake or tobacco smoking (p for trend = 0.0006; adjusted relative risk for the highest vs. lowest tertile of intake = 0.29, 95% confidence interval: 0.13, 0.67). Green tea drinking was unrelated to
Parkinson's disease
risk. Diet had no strong influence on risk. Ingredients of black tea other than
caffeine
appear to be responsible for the beverage's inverse association with
Parkinson's disease
.
...
PMID:Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. 1815 41
Parkinson's disease
(PD) is one of the most common neurodegenerative diseases. Recent epidemiological studies suggest that
caffeine
, one of the major components of coffee, has a protective effect against developing PD. However, the detailed mechanisms of how
caffeine
suppresses neuronal death have not been fully elucidated. We investigated the cytoprotective mechanisms of
caffeine
using human dopaminergic neuroblastoma SH-SY5Y cells as a PD model.
Caffeine
prevented the apoptotic cell death induced by serum/retinoic acid (RA) deprivation, MPP+, rotenone, and 6-OHDA in SH-SY5Y cells in a dose dependent manner.
Caffeine
lowered caspase-3 activity induced by serum/RA deprivation and 6-OHDA administration, and also decreased the number of apoptotic condensed and/or fragmented nuclei. Akt was phosphorylated 60 min after
caffeine
administration in a dose dependent manner; PI3K inhibitors, wortmannin and LY294002 canceled this cytoprotective effect of
caffeine
. On the other hand, MAPKs such as Erk1/2, p38, or JNK were not activated by
caffeine
. These results suggest that
caffeine
has a cytoprotective effect due to the activation of the PI3K/Akt pathways in SH-SY5Y cells.
...
PMID:Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. 1820 23
Caffeine
, the most consumed psychoactive drug and non-specific adenosine receptor antagonist, has recently been shown to exert a neuroprotective effect against brain injury in animal models of
Parkinson's disease
(PD) and stroke. However, the effects of
caffeine
on traumatic brain injury (TBI) are not known. In this study, we investigated the effects of acute and chronic
caffeine
treatment on brain injury in a cortical-impact model of TBI in mice. Following TBI, neurological deficits, cerebral edema, as well as inflammatory cell infiltration were all significantly attenuated in mice pretreated chronically (for 3 weeks) with
caffeine
in drinking water compared with the mice pretreated with saline. Furthermore, we found that chronic
caffeine
treatment attenuated glutamate release and inflammatory cytokine production, effects that were correlated with an upregulation of brain A1 receptor mRNA. By contrast, acute treatment with
caffeine
(i.p. injection, 30 min before TBI) was not effective in protecting against TBI-induced brain injury. These results suggest that chronic (but not acute)
caffeine
treatment attenuates brain injury, possibly by A1 receptor-mediated suppression of glutamate release and inhibition of excessive inflammatory cytokine production. These results highlight the potential benefit of chronic
caffeine
intake for preventing TBI and provide a rationale for the epidemiological investigation of the potential association between TBI and human
caffeine
intake.
...
PMID:Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model. 1820 47
This review will examine how dopamine, a monoamine neurotransmitter, and adenosine, a neuromodulator, regulate behavioral activation, primarily as reflected by locomotor activity, in rodents. Complex interactions among 2 major types of adenosine receptors (A1AR and A2AAR) and 2 dopamine receptors (D1R and D2R) occur due to physical interactions that alter their ligand-binding properties and subsequent effects on common postreceptor signaling molecules. The output from these interactions in striatum modulates neurotransmission and subsequently influences spontaneous locomotor activity.
Caffeine
is a nonselective adenosine receptor antagonist that blocks 2 major types of adenosine receptors, A1AR and A2AAR, in the brain. Pharmacologic manipulation of these receptors with drugs such as
caffeine
offers potential therapeutic benefit for treatment of
Parkinson disease
.
...
PMID:Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation. 1824 65
The authors examined whether a diet that increases plasma urate level is also related to reduced risk of
Parkinson's disease
(PD). The study population comprised 47,406 men in the Health Professionals Follow-up Study. The potential effect of diet on plasma urate level was estimated by regressing plasma urate on intakes of selected foods and nutrients in a subsample of 1,387 men. Coefficients of this regression model were then used to calculate a dietary urate index for all cohort participants. Multivariate relative risks of PD were estimated by means of Cox proportional hazards models. After 14 years of follow-up (1986-2000), the authors documented 248 incident cases of PD. A higher dietary urate index was associated with a lower risk of PD (top quintile vs. bottom: relative risk = 0.47, p-trend = 0.0008), after adjustment for age, smoking,
caffeine
intake, and other potential confounders. This association remained strong and significant after further adjustment for each component of the index individually (p-trend < 0.02 for each). These data support urate as a potentially protective factor in PD and suggest that dietary changes expected to increase plasma urate level may contribute to lower risk of PD. These potential benefits, however, should be weighed against expected adverse effects on risk of gout and other chronic diseases.
...
PMID:Diet, urate, and Parkinson's disease risk in men. 1832 73
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>